Use of convalescent plasma in serious patients by COVID-19: Qualitative case series review
DOI:
https://doi.org/10.33448/rsd-v10i1.11988Keywords:
COVID-19; Convalescent plasma; Immunological Therapy; Safety; Effectiveness.Abstract
The objective of this research was to find and evaluate the efficacy and safety of the use of plasma from recovered patients for the treatment of critically ill patients with COVID-19 (SARS-CoV-2), through a series of cases. The search took place in scientific databases such as Lilacs, MEDLINE, Google Academics, Scielo and Science Direct. After applying the filters for advanced search, and tracking by title, the pre-included abstracts were read, then evaluated in full for data extraction and synthesis of information and results. At the end, three case series observational studies were included. The patients in the study were using medications in a parallel way to the procedure (eg: antibiotics, antiviral drugs and steroids). Patients, in general, had improvements in most clinical symptoms, as well as in the decrease in SARS-CoV-2 viral titers, no adverse event was passive to alert. It is concluded that the evidences found in this work are heterogeneous and with a lot of limitations, about transfused dose, time of treatment and criteria to choose the patients, therefore, due to the presented restrictions, it is necessary to carry out clinical trials with outlined study designs, to certify the safety and effectiveness of the treatment.
References
Abdullah, S. F., Anees, R. & Alaa, M. G. (2020). Adaptive Immune Responses to SARS-CoV-2 and Prophylactic Vaccines for COVID-19. GSJ: Volume 8, Issue 5.
Anvisa-A. Agência Nacional de Vigilância Sanitária. (2020). Nº 19/2020/SEI/GSTCO/DIRE1/ANVISA. Nota Técnica, Aspectos regulatórios do uso de plasma de doador convalescente para tratamento da Covid-19. https://docs.bvsalud.org/biblioref/2020/05/1096174/plasmaconvalescente-covid19.pdf.
Anvisa-B. Agência Nacional de Vigilância Sanitária. (2020). Nº 21/2020-CGSH/DAET/SAES/MS. Nota Técnica, Coleta e transfusão de plasma de convalescentes para uso experimental no tratamento de pacientes com COVID-19. http://www.mpgo.mp.br/portal/arquivos/2020/08/28/17 _14_32_355_Nota_T%C3%A9cnica_n_21_2020_CGSH_DAET_SAES_MS_Orientacoes_Plasma_convalescente_COVID_19.pdf.
Anvisa-C. Agência Nacional de Vigilância Sanitária. (2000). Resolução de Diretoria Colegiada - RDC Nº 73, DE 3 DE AGOSTO DE 2000. Dispõe sobre o Programa Nacional de Sangue e Hemoderivados, regula o uso e a disponibilidade do Plasma Fresco Congelado Excedente do Uso Terapêutico no Brasil e dá outras providências. http://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2000/res0073_03_08_2000.html.
Anvisa-D. Agência Nacional de Vigilância Sanitária. (2014). Resolução da Diretoria Colegiada - RDC nº 34, de 11 de junho de 2014. Dispõe sobre as Boas Práticas no Ciclo do Sangue. https://saude.rs.gov.br/upload/arquivos/carga20170553/04145350-rdc-anvisa-34-2014.pdf.
Aromataris, E., Munn, Z., Barker, T., Moola, S., Tufanaru, C., Stern, C., McArthur, A. & Stephenson, M. (2020). Methodological quality of case series studies, JBI Evidence Synthesis.
Casadevall, A. & Pirofski, L. (2020). The convalescent sera option for containing COVID-19. J Clin Invest, 130(4):1545-1548.
Cheng, Y., Wong, R., Soo, Y. O. Y., Wong, W. S., Lee, C. K., Ng, M. H. L., Chan, P., Wong, K. C., Leung, C. B. & Cheng, G. (2020). Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 24: 44–46.
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., Peng, C., Yuan, M., Huang, J., Wang, Z., Yu, J., Gao, X., Wang, D., Yu, X., Li, L., Zhang, J., Wu, X., Li, B., Xu, P., Chen, W., Peng, Yan., Hu, Y., Lin, L., Liu, X., Huang, S., Zhou, Z., Zhang, Wang, Y., Zhang, Z., Deng, Z., Xia, Z., Gong, Q., Zhang, W., Zheng, X., Liu, Y., Yang, H., Zhou, D., Yu, D., Hou, J., Shi, Z., Chen, S., Chen, Z., Zhang, X. & Yang, X. (2020). Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences of USA (PNAS). https://www.pnas.org/content/117/17/9490.
Food and Drug Administration (FDA). (2020). Recommendations for Investigational COVID-19 Convalescent Plasma. Development & Approval Process (CBER). https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemptionide-process cber/recommendations-investigational-covid-19-convalescent-plasma.
Maxmen, A. (2020). How blood from coronavirus survivors might save lives. A Nature Research Journal (Nature). https://www.nature.com/articles/d41586-020-00895-8.
Ministério da Saúde do Brasil. (2020). Coordenação De Gestão De Protocolos Clínicos e Diretrizes Terapêuticas. Diretrizes Para Diagnóstico e Tratamento Da Covid-19, Versão 4. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde – SCTIE. https://saude.rs.gov.br/upload/a rquivos/202004/14140600-2-ms-diretrizes-covid-v2-9-4.pdf.
Pereira, A. S., Shitsuka D. M., Parreira F. J. & Shitsuka, R. (2018). Metodologia da pesquisa científica. [e-book]. Santa Maria. Ed. UAB/NTE/UFSM. https://repositorio.ufsm.br/bitstream/handle/1/15824/Lic_Computacao_Metodologia-Pesquisa-Cientifica.pdf?sequence=1.
Pessoa, B. M. S., Barroso, C. T., Vila, D. J. C., Barbosa, E. M. L., Seffair, I. A., Melo, J. V. O., Becil, J. N., Rodrigues, N. M. V., Freitas, P. H. A. G., Rocha, R. B., Bentes, T. M., Rodrigues, T. F. & Santos, M.C. (2020). Imunoterapias No Tratamento Da Covid-19. Revista Desafios. 7. COVID-19.
Rubin, R. (2020). Testing an Old Therapy Against a New Disease: Convalescent Plasma for COVID-19. JAMA. 323(21).
Salazar, E., Perez, K., Ashraf, M., Chen, J., Castillo, B., Christensen, P. A., Eubank, T., Bernard, D. W., Eagar, T. N., Long, S. W., Subedi, S., Olsen, R. J., Leveque, C., Schwartz, M. R., Dey, M., Chavez-East, C., Rogers, J., Shehabeldin, A., Joseph, D., Williams, G., Thomas, K., Masud, F., Talley, C., Dlouhy, K. G., Lopez, B. V., Hampton, K., Lavinder, J., Gollihar, J. D., Maranhão, A. C., Ippolito, G. C., Saavedra, M. O., Cantu, C. C., Yerramilli, P., Pruitt, L., & Musser, J. M. (2020). Treatment of Coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. The American Journal of Pathology, 190, 2290-2303.
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, Li., Wei, J., Xiao, H., Yang, Y., Qu, J., Qing, L., Chen, L., Xu, Z., Peng, L., Li, Y., Zheng, H., Chen, F., Huang, K., Jiang, Y., Liu, D., Zhang, Z., Liu, Y. & Liu, L. (2020). Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA.
Sullivan, H. C. & Roback, J. D. (2020). Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic. Transfusion Medicine Reviews. 34. 145–150.
Sun, M., A potentially effective treatment for COVID-19: A systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease. International Journal of Infectious Diseases, 98, 334–346.2020.
Wu, F., Zhao, S., Yu, B., Chen, Y. M., Wang, W., Song, Z. G., Hu, Y., Tao, Z. W., Tian, J. H., Pei, Y. Y., Yuan, M. L., Zhang, Y. L., Dai, Y. L., Wang, Q. M., Zheng, J. J., Xu, L., Holmes, E. C., & Zhang, Y. Z. (2020). A new coronavirus associated with human respiratory disease in China. Nature, 579, 265–269.
Ye, M., Fu, D., Ren, Y., Wang, F., Wang, D., Zhang, F., Xia, X. & Lv, T. (2020). Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China. J Med Virol.1–12.
Xu, X., Chen, P., Wang, J., Feng, J., Zhou, H., Li, X., Zhong, W. & Hao, P. (2020). Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci, 63, 457–460.
Zhang, B., Liu, S., Tan, T., Huang, W., Dong, Y., Chen, L., Chen, O., Zhang, L., Zhong, Q., Zhang, X., Zou, Y. & Zhang, S. (2020). Treatment with Convalescent Plasma for Critically Ill Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection. CHEST, 158(1): 9-13.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Gabriel Couto Rocha; Aquiles Assunção Camelier; Lorhany dos Santos Santana; Fernanda Warken Rosa Camelier; Roberto Rodrigues Bandeira Tosta Maciel
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
